LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 21

Search options

  1. Article: Minimal impact of ZAP on lentiviral vector production and transduction efficiency.

    Sertkaya, Helin / Hidalgo, Laura / Ficarelli, Mattia / Kmiec, Dorota / Signell, Adrian W / Ali, Sadfer / Parker, Hannah / Wilson, Harry / Neil, Stuart J D / Malim, Michael H / Vink, Conrad A / Swanson, Chad M

    Molecular therapy. Methods & clinical development

    2021  Volume 23, Page(s) 147–157

    Abstract: The antiviral protein ZAP binds CpG dinucleotides in viral RNA to inhibit replication. This has likely led to the CpG suppression observed in many RNA viruses, including retroviruses. Sequences added to retroviral vector genomes, such as internal ... ...

    Abstract The antiviral protein ZAP binds CpG dinucleotides in viral RNA to inhibit replication. This has likely led to the CpG suppression observed in many RNA viruses, including retroviruses. Sequences added to retroviral vector genomes, such as internal promoters, transgenes, or regulatory elements, substantially increase CpG abundance. Because these CpGs could allow retroviral vector RNA to be targeted by ZAP, we analyzed whether it restricts vector production, transduction efficiency, and transgene expression. Surprisingly, even though CpG-high HIV-1 was efficiently inhibited by ZAP in HEK293T cells, depleting ZAP did not substantially increase lentiviral vector titer using several packaging and genome plasmids. ZAP overexpression also did not inhibit lentiviral vector titer. In addition, decreasing CpG abundance in a lentiviral vector genome did not increase its titer, and a gammaretroviral vector derived from murine leukemia virus was not substantially restricted by ZAP. Overall, we show that the increased CpG abundance in retroviral vectors relative to the wild-type retroviruses they are derived from does not intrinsically sensitize them to ZAP. Further understanding of how ZAP specifically targets transcripts to inhibit their expression may allow the development of CpG sequence contexts that efficiently recruit or evade this antiviral system.
    Language English
    Publishing date 2021-08-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2872938-9
    ISSN 2329-0501 ; 2329-0501
    ISSN (online) 2329-0501
    ISSN 2329-0501
    DOI 10.1016/j.omtm.2021.08.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave.

    Sweeney, Nicola / Merrick, Blair / Pedro Galão, Rui / Pickering, Suzanne / Botgros, Alina / Wilson, Harry D / Signell, Adrian W / Betancor, Gilberto / Tan, Mark Kia Ik / Ramble, John / Kouphou, Neophytos / Acors, Sam / Graham, Carl / Seow, Jeffrey / MacMahon, Eithne / Neil, Stuart J D / Malim, Michael H / Doores, Katie / Douthwaite, Sam /
    Batra, Rahul / Nebbia, Gaia / Edgeworth, Jonathan D

    PloS one

    2021  Volume 16, Issue 4, Page(s) e0249791

    Abstract: During the first wave of the global COVID-19 pandemic the clinical utility and indications for SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy serological assays required rapid evaluation of their performance ... ...

    Abstract During the first wave of the global COVID-19 pandemic the clinical utility and indications for SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy serological assays required rapid evaluation of their performance characteristics. We undertook an internal validation of a CE marked lateral flow immunoassay (LFIA) (SureScreen Diagnostics) using serum from SARS-CoV-2 RNA positive individuals and pre-pandemic samples. This was followed by the delivery of a same-day named patient SARS-CoV-2 serology service using LFIA on vetted referrals at central London teaching hospital with clinical interpretation of result provided to the direct care team. Assay performance, source and nature of referrals, feasibility and clinical utility of the service, particularly benefit in clinical decision-making, were recorded. Sensitivity and specificity of LFIA were 96.1% and 99.3% respectively. 113 tests were performed on 108 participants during three-week pilot. 44% participants (n = 48) had detectable antibodies. Three main indications were identified for serological testing; new acute presentations potentially triggered by recent COVID-19 e.g. pulmonary embolism (n = 5), potential missed diagnoses in context of a recent COVID-19 compatible illness (n = 40), and making infection control or immunosuppression management decisions in persistently SARS-CoV-2 RNA PCR positive individuals (n = 6). We demonstrate acceptable performance characteristics, feasibility and clinical utility of using a LFIA that detects anti-spike antibodies to deliver SARS-CoV-2 serology service in adults and children. Greatest benefit was seen where there is reasonable pre-test probability and results can be linked with clinical advice or intervention. Experience from this pilot can help inform practicalities and benefits of rapidly implementing new tests such as LFIAs into clinical service as the pandemic evolves.
    MeSH term(s) Adult ; COVID-19/blood ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19 Serological Testing ; Female ; Humans ; Male ; Pandemics ; SARS-CoV-2/metabolism ; Syndrome
    Language English
    Publishing date 2021-04-07
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't ; Validation Study
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0249791
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission.

    Snell, Luke B / Fisher, Chloe L / Taj, Usman / Stirrup, Oliver / Merrick, Blair / Alcolea-Medina, Adela / Charalampous, Themoula / Signell, Adrian W / Wilson, Harry D / Betancor, Gilberto / Kia Ik, Mark Tan / Cunningham, Emma / Cliff, Penelope R / Pickering, Suzanne / Galao, Rui Pedro / Batra, Rahul / Neil, Stuart J D / Malim, Michael H / Doores, Katie J /
    Douthwaite, Sam T / Nebbia, Gaia / Edgeworth, Jonathan D / Awan, Ali R

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2021  Volume 28, Issue 1, Page(s) 93–100

    Abstract: Objectives: To analyse nosocomial transmission in the early stages of the coronavirus 2019 (COVID-19) pandemic at a large multisite healthcare institution. Nosocomial incidence is linked with infection control interventions.: Methods: Viral genome ... ...

    Abstract Objectives: To analyse nosocomial transmission in the early stages of the coronavirus 2019 (COVID-19) pandemic at a large multisite healthcare institution. Nosocomial incidence is linked with infection control interventions.
    Methods: Viral genome sequence and epidemiological data were analysed for 574 consecutive patients, including 86 nosocomial cases, with a positive PCR test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first 19 days of the pandemic.
    Results: Forty-four putative transmission clusters were found through epidemiological analysis; these included 234 cases and all 86 nosocomial cases. SARS-CoV-2 genome sequences were obtained from 168/234 (72%) of these cases in epidemiological clusters, including 77/86 nosocomial cases (90%). Only 75/168 (45%) of epidemiologically linked, sequenced cases were not refuted by applying genomic data, creating 14 final clusters accounting for 59/77 sequenced nosocomial cases (77%). Viral haplotypes from these clusters were enriched 1-14x (median 4x) compared to the community. Three factors implicated unidentified cases in transmission: (a) community-onset or indeterminate cases were absent in 7/14 clusters (50%), (b) four clusters (29%) had additional evidence of cryptic transmission, and (c) in three clusters (21%) diagnosis of the earliest case was delayed, which may have facilitated transmission. Nosocomial cases decreased to low levels (0-2 per day) despite continuing high numbers of admissions of community-onset SARS-CoV-2 cases (40-50 per day) and before the impact of introducing universal face masks and banning hospital visitors.
    Conclusion: Genomics was necessary to accurately resolve transmission clusters. Our data support unidentified cases-such as healthcare workers or asymptomatic patients-as important vectors of transmission. Evidence is needed to ascertain whether routine screening increases case ascertainment and limits nosocomial transmission.
    MeSH term(s) COVID-19/epidemiology ; COVID-19/transmission ; Cross Infection/epidemiology ; Disease Outbreaks ; Genome, Viral ; Genomics ; Hospitals ; Humans ; Pandemics ; SARS-CoV-2/genetics
    Language English
    Publishing date 2021-08-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1470-9465 ; 1198-743X
    ISSN (online) 1469-0691
    ISSN 1470-9465 ; 1198-743X
    DOI 10.1016/j.cmi.2021.07.040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome.

    Shaw, Andrew M / Hyde, Christopher / Merrick, Blair / James-Pemberton, Philip / Squires, Bethany K / Olkhov, Rouslan V / Batra, Rahul / Patel, Amita / Bisnauthsing, Karen / Nebbia, Gaia / MacMahon, Eithne / Douthwaite, Sam / Malim, Michael / Neil, Stuart / Martinez Nunez, Rocio / Doores, Katie / Mark, Tan Kia Ik / Signell, Adrian W / Betancor, Gilberto /
    Wilson, Harry D / Galão, Rui Pedro / Pickering, Suzanne / Edgeworth, Jonathan D

    The Analyst

    2020  Volume 145, Issue 16, Page(s) 5638–5646

    Abstract: An evaluation of a rapid portable gold-nanotechnology measuring SARS-CoV-2 IgM, IgA and IgG antibody concentrations against spike 1 (S1), spike 2 (S) and nucleocapsid (N) was conducted using serum samples from 74 patients tested for SARS-CoV-2 RNA on ... ...

    Abstract An evaluation of a rapid portable gold-nanotechnology measuring SARS-CoV-2 IgM, IgA and IgG antibody concentrations against spike 1 (S1), spike 2 (S) and nucleocapsid (N) was conducted using serum samples from 74 patients tested for SARS-CoV-2 RNA on admission to hospital, and 47 historical control patients from March 2019. 59 patients were RNA(+) and 15 were RNA(-). A serum (±) classification was derived for all three antigens and a quantitative serological profile was obtained. Serum(+) was identified in 30% (95% CI 11-48) of initially RNA(-) patients, in 36% (95% CI 17-54) of RNA(+) patients before 10 days, 77% (95% CI 67-87) between 10 and 20 days and 95% (95% CI 86-100) after 21 days. The patient-level diagnostic accuracy relative to RNA(±) after 10 days displayed 88% sensitivity (95% CI 75-95) and 75% specificity (95% CI 22-99), although specificity compared with historical controls was 100% (95%CI 91-100). This study provides robust support for further evaluation and validation of this novel technology in a clinical setting and highlights challenges inherent in assessment of serological tests for an emerging disease such as COVID-19.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral/analysis ; Antibodies, Viral/immunology ; Betacoronavirus/immunology ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques ; Cohort Studies ; Coronavirus Infections/blood ; Coronavirus Infections/diagnosis ; Coronavirus Nucleocapsid Proteins ; False Negative Reactions ; Female ; Gold/chemistry ; Humans ; Immunoglobulin A/analysis ; Immunoglobulin A/immunology ; Immunoglobulin G/analysis ; Immunoglobulin G/immunology ; Immunoglobulin M/analysis ; Immunoglobulin M/immunology ; Male ; Metal Nanoparticles/chemistry ; Middle Aged ; Nucleocapsid Proteins/immunology ; Pandemics ; Phosphoproteins ; Pneumonia, Viral/blood ; Pneumonia, Viral/diagnosis ; SARS-CoV-2 ; Sensitivity and Specificity ; Serologic Tests/methods ; Spike Glycoprotein, Coronavirus/immunology ; Young Adult
    Chemical Substances Antibodies, Viral ; Coronavirus Nucleocapsid Proteins ; Immunoglobulin A ; Immunoglobulin G ; Immunoglobulin M ; Nucleocapsid Proteins ; Phosphoproteins ; Spike Glycoprotein, Coronavirus ; nucleocapsid phosphoprotein, SARS-CoV-2 ; spike protein, SARS-CoV-2 ; Gold (7440-57-5)
    Keywords covid19
    Language English
    Publishing date 2020-07-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 210747-8
    ISSN 1364-5528 ; 0003-2654
    ISSN (online) 1364-5528
    ISSN 0003-2654
    DOI 10.1039/d0an01066a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings.

    Pickering, Suzanne / Betancor, Gilberto / Galão, Rui Pedro / Merrick, Blair / Signell, Adrian W / Wilson, Harry D / Kia Ik, Mark Tan / Seow, Jeffrey / Graham, Carl / Acors, Sam / Kouphou, Neophytos / Steel, Kathryn J A / Hemmings, Oliver / Patel, Amita / Nebbia, Gaia / Douthwaite, Sam / O'Connell, Lorcan / Luptak, Jakub / McCoy, Laura E /
    Brouwer, Philip / van Gils, Marit J / Sanders, Rogier W / Martinez Nunez, Rocio / Bisnauthsing, Karen / O'Hara, Geraldine / MacMahon, Eithne / Batra, Rahul / Malim, Michael H / Neil, Stuart J D / Doores, Katie J / Edgeworth, Jonathan D

    PLoS pathogens

    2020  Volume 16, Issue 9, Page(s) e1008817

    Abstract: There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement to existing diagnostic capabilities and for determining community seroprevalence. We therefore evaluated the performance of a variety of antibody testing ... ...

    Abstract There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement to existing diagnostic capabilities and for determining community seroprevalence. We therefore evaluated the performance of a variety of antibody testing technologies and their potential use as diagnostic tools. Highly specific in-house ELISAs were developed for the detection of anti-spike (S), -receptor binding domain (RBD) and -nucleocapsid (N) antibodies and used for the cross-comparison of ten commercial serological assays-a chemiluminescence-based platform, two ELISAs and seven colloidal gold lateral flow immunoassays (LFIAs)-on an identical panel of 110 SARS-CoV-2-positive samples and 50 pre-pandemic negatives. There was a wide variation in the performance of the different platforms, with specificity ranging from 82% to 100%, and overall sensitivity from 60.9% to 87.3%. However, the head-to-head comparison of multiple sero-diagnostic assays on identical sample sets revealed that performance is highly dependent on the time of sampling, with sensitivities of over 95% seen in several tests when assessing samples from more than 20 days post onset of symptoms. Furthermore, these analyses identified clear outlying samples that were negative in all tests, but were later shown to be from individuals with mildest disease presentation. Rigorous comparison of antibody testing platforms will inform the deployment of point-of-care technologies in healthcare settings and their use in the monitoring of SARS-CoV-2 infections.
    MeSH term(s) Adult ; Aged ; Antibodies, Viral/analysis ; Betacoronavirus ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques ; Community Health Services ; Coronavirus Infections/diagnosis ; Coronavirus Nucleocapsid Proteins ; Enzyme-Linked Immunosorbent Assay ; Female ; Hospitals ; Humans ; Immunoassay ; Luminescent Measurements ; Male ; Middle Aged ; Nucleocapsid Proteins/immunology ; Pandemics ; Phosphoproteins ; Pneumonia, Viral/diagnosis ; Point-of-Care Systems ; SARS-CoV-2 ; Sensitivity and Specificity ; Serologic Tests/methods ; Spike Glycoprotein, Coronavirus/immunology
    Chemical Substances Antibodies, Viral ; Coronavirus Nucleocapsid Proteins ; Nucleocapsid Proteins ; Phosphoproteins ; Spike Glycoprotein, Coronavirus ; nucleocapsid phosphoprotein, SARS-CoV-2 ; spike protein, SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-09-24
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2205412-1
    ISSN 1553-7374 ; 1553-7374
    ISSN (online) 1553-7374
    ISSN 1553-7374
    DOI 10.1371/journal.ppat.1008817
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: results from a pilot service

    Sweeney, Nicola / Merrick, Blair / Pickering, Suzanne / Pedro Galao, Rui / Botgros, Alina / Wilson, Harry D. / Signell, Adrian W. / Betancor, Gilberto / Tan, Mark Kia Ik / Ramble, John / Kouphou, Neophytos / Acors, Sam / Graham, Carl / Seow, Jeffrey / MacMahon, Eithne / Neil, Stuart J. D. / Malim, Michael H. / Doores, Katie / Douthwaite, Sam /
    Batra, Rahul / Nebbia, Gaia / Edgeworth, Jonathan D.

    medRxiv

    Abstract: Objectives: Determine indications and clinical utility of SARS-CoV-2 serology testing in adults and children. Design: Prospective evaluation of initial three weeks of a daily Monday to Friday pilot SARS-CoV-2 serology service for patients. Setting: Early ...

    Abstract Objectives: Determine indications and clinical utility of SARS-CoV-2 serology testing in adults and children. Design: Prospective evaluation of initial three weeks of a daily Monday to Friday pilot SARS-CoV-2 serology service for patients. Setting: Early post 9first-wave9 SARS-CoV-2 transmission period at single centre London teaching hospital that provides care to the local community, as well as regional and national referral pathways for specialist services. Participants: 110 (72 adults, 38 children, age range 0-83 years, 52.7% female (n=58)). Interventions: Patient serum from vetted referrals tested on CE marked and internally validated lateral flow immunoassay (LFIA) (SureScreen Diagnostics) detecting antibodies to SARS-CoV-2 spike proteins, with result and clinical interpretation provided to the direct care team. Main outcome measures: Performance characteristics, source and nature of referrals, feasibility and clinical utility of the service, particularly the benefit for clinical decision-making. Results: The LFIA was deemed suitable for clinical advice and decision making following evaluation with 310 serum samples from SARS-CoV-2 PCR positive patients and 300 pre-pandemic samples, giving a sensitivity and specificity of 96.1% and 99.3% respectively. For the pilot, 115 referrals were received leading to 113 tests performed on 108 participants (sample not available for two participants); paediatrics (n=35), medicine (n=69), surgery (n=2) and general practice (n=2). 43.4% participants (n=49) had detectable antibodies to SARS-CoV-2. There were three main indications for serology; new acute presentations potentially triggered by recent COVID-19 infection e.g. PIMS-TS (n=26) and pulmonary embolism (n=5), potential missed diagnoses in context of a recent compatible illness (n=40), and making infection control and immunosuppression treatment decisions in persistently SARS-CoV-2 RNA PCR positive individuals (n=6). Conclusions: This study shows acceptable performance characteristics, feasibility and clinical utility of a SARS-CoV-2 serology service using a rapid, inexpensive and portable assay for adults and children presenting with a range of clinical indications. Results correlated closely with a confirmatory in-house ELISA. The study showed the benefit of introducing a serology service where there is a reasonable pre-test probability, and the result can be linked with clinical advice or intervention. Experience thus far is that the volume of requests from hospital referral routes are manageable within existing clinical and laboratory services; however, the demand from community referrals has not yet been assessed. Given recent evidence for a rapid decline in antibodies, particularly following mild infection, there is likely a limited window of opportunity to realise the benefit of serology testing for individuals infected during the 9first-wave9 before they potentially fall below a measurable threshold. Rapidly expanding availability of serology services for NHS patients will also help understand the long-term implications of serostatus and prior infection in different patient groups, particularly before emergence of any 9second-wave9 outbreak or introduction of a vaccination programme.
    Keywords covid19
    Language English
    Publishing date 2020-07-11
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2020.07.10.20150540
    Database COVID19

    Kategorien

  7. Article: Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome

    Shaw, Andrew M / Hyde, Christopher / Merrick, Blair / James-Pemberton, Philip / Squires, Bethany K / Olkhov, Rouslan V / Batra, Rahul / Patel, Amita / Bisnauthsing, Karen / Nebbia, Gaia / MacMahon, Eithne / Douthwaite, Sam / Malim, Michael / Neil, Stuart / Martinez Nunez, Rocio / Doores, Katie / Mark, Tan Kia Ik / Signell, Adrian W / Betancor, Gilberto /
    Wilson, Harry D / Galão, Rui Pedro / Pickering, Suzanne / Edgeworth, Jonathan D

    Analyst

    Abstract: An evaluation of a rapid portable gold-nanotechnology measuring SARS-CoV-2 IgM, IgA and IgG antibody concentrations against spike 1 (S1), spike 2 (S) and nucleocapsid (N) was conducted using serum samples from 74 patients tested for SARS-CoV-2 RNA on ... ...

    Abstract An evaluation of a rapid portable gold-nanotechnology measuring SARS-CoV-2 IgM, IgA and IgG antibody concentrations against spike 1 (S1), spike 2 (S) and nucleocapsid (N) was conducted using serum samples from 74 patients tested for SARS-CoV-2 RNA on admission to hospital, and 47 historical control patients from March 2019. 59 patients were RNA(+) and 15 were RNA(-). A serum (±) classification was derived for all three antigens and a quantitative serological profile was obtained. Serum(+) was identified in 30% (95% CI 11-48) of initially RNA(-) patients, in 36% (95% CI 17-54) of RNA(+) patients before 10 days, 77% (95% CI 67-87) between 10 and 20 days and 95% (95% CI 86-100) after 21 days. The patient-level diagnostic accuracy relative to RNA(±) after 10 days displayed 88% sensitivity (95% CI 75-95) and 75% specificity (95% CI 22-99), although specificity compared with historical controls was 100% (95%CI 91-100). This study provides robust support for further evaluation and validation of this novel technology in a clinical setting and highlights challenges inherent in assessment of serological tests for an emerging disease such as COVID-19.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #637680
    Database COVID19

    Kategorien

  8. Article ; Online: Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome

    Shaw, Andrew M. / Hyde, Christopher / Merrick, Blair / James-Pemberton, Philip / Squires, Bethany K. / Olkhov, Rouslan V. / Batra, Rahul / Patel, Amita / Bisnauthsing, Karen / Nebbia, Gaia / MacMahon, Eithne / Douthwaite, Sam / Malim, Michael / Neil, Stuart / Martinez Nunez, Rocio / Doores, Katie / Mark, Tan Kia Ik / Signell, Adrian W. / Betancor, Gilberto /
    Wilson, Harry D. / Galão, Rui Pedro / Pickering, Suzanne / Edgeworth, Jonathan D.

    The Analyst

    2020  Volume 145, Issue 16, Page(s) 5638–5646

    Abstract: An evaluation of a rapid portable gold-nanotechnology measuring SARS-CoV-2 IgM, IgA and IgG antibody response to spike 1 (S1), spike 2 (S) and nucleocapsid (N) antigens using serum from 74 RNA(+) patients and RNA(+) 47 control patients. ...

    Abstract An evaluation of a rapid portable gold-nanotechnology measuring SARS-CoV-2 IgM, IgA and IgG antibody response to spike 1 (S1), spike 2 (S) and nucleocapsid (N) antigens using serum from 74 RNA(+) patients and RNA(+) 47 control patients.
    Keywords Analytical Chemistry ; Spectroscopy ; Electrochemistry ; Biochemistry ; Environmental Chemistry ; covid19
    Language English
    Publisher Royal Society of Chemistry (RSC)
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 210747-8
    ISSN 0003-2654
    ISSN 0003-2654
    DOI 10.1039/d0an01066a
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.

    Khair, Duaa O / Bax, Heather J / Mele, Silvia / Crescioli, Silvia / Pellizzari, Giulia / Khiabany, Atousa / Nakamura, Mano / Harris, Robert J / French, Elise / Hoffmann, Ricarda M / Williams, Iwan P / Cheung, Anthony / Thair, Benjamin / Beales, Charlie T / Touizer, Emma / Signell, Adrian W / Tasnova, Nahrin L / Spicer, James F / Josephs, Debra H /
    Geh, Jenny L / MacKenzie Ross, Alastair / Healy, Ciaran / Papa, Sophie / Lacy, Katie E / Karagiannis, Sophia N

    Frontiers in immunology

    2019  Volume 10, Page(s) 453

    Abstract: The immune system employs several checkpoint pathways to regulate responses, maintain homeostasis and prevent self-reactivity and autoimmunity. Tumor cells can hijack these protective mechanisms to enable immune escape, cancer survival and proliferation. ...

    Abstract The immune system employs several checkpoint pathways to regulate responses, maintain homeostasis and prevent self-reactivity and autoimmunity. Tumor cells can hijack these protective mechanisms to enable immune escape, cancer survival and proliferation. Blocking antibodies, designed to interfere with checkpoint molecules CTLA-4 and PD-1/PD-L1 and counteract these immune suppressive mechanisms, have shown significant success in promoting immune responses against cancer and can result in tumor regression in many patients. While inhibitors to CTLA-4 and the PD-1/PD-L1 axis are well-established for the clinical management of melanoma, many patients do not respond or develop resistance to these interventions. Concerted efforts have focused on combinations of approved therapies aiming to further augment positive outcomes and survival. While CTLA-4 and PD-1 are the most-extensively researched targets, results from pre-clinical studies and clinical trials indicate that novel agents, specific for checkpoints such as A2AR, LAG-3, IDO and others, may further contribute to the improvement of patient outcomes, most likely in combinations with anti-CTLA-4 or anti-PD-1 blockade. This review discusses the rationale for, and results to date of, the development of inhibitory immune checkpoint blockade combination therapies in melanoma. The clinical potential of new pipeline therapeutics, and possible future therapy design and directions that hold promise to significantly improve clinical prognosis compared with monotherapy, are discussed.
    MeSH term(s) Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; B7-H1 Antigen/immunology ; CTLA-4 Antigen/immunology ; Humans ; Immune System/drug effects ; Immune System/immunology ; Immunotherapy/methods ; Melanoma/immunology ; Melanoma/therapy
    Chemical Substances Antibodies, Monoclonal ; B7-H1 Antigen ; CTLA-4 Antigen
    Language English
    Publishing date 2019-03-19
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2019.00453
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation.

    Lista, Maria Jose / Matos, Pedro M / Maguire, Thomas J A / Poulton, Kate / Ortiz-Zapater, Elena / Page, Robert / Sertkaya, Helin / Ortega-Prieto, Ana M / O'Byrne, Aoife M / Bouton, Clement / Dickenson, Ruth E / Ficarelli, Mattia / Jimenez-Guardeño, Jose M / Howard, Mark / Betancor, Gilberto / Galao, Rui Pedro / Pickering, Suzanne / Signell, Adrian W / Wilson, Harry /
    Cliff, Penelope / Ik, Mark Tan Kia / Patel, Amita / MacMahon, Eithne / Cunningham, Emma / Doores, Katie / Agromayor, Monica / Martin-Serrano, Juan / Perucha, Esperanza / Mischo, Hannah E / Shankar-Hari, Manu / Batra, Rahul / Edgeworth, Jonathan / Zuckerman, Mark / Malim, Michael H / Neil, Stuart / Martinez-Nunez, Rocio Teresa

    medRxiv : the preprint server for health sciences

    2021  

    Abstract: There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not have the capacity to develop these and/or perform manual processing. We provide multiple workflows for ... ...

    Abstract There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not have the capacity to develop these and/or perform manual processing. We provide multiple workflows for SARS-CoV-2 nucleic acid detection in clinical samples by comparing several commercially available RNA extraction methods: QIAamp Viral RNA Mini Kit (QIAgen), RNAdvance Blood/Viral (Beckman) and Mag-Bind Viral DNA/RNA 96 Kit (Omega Bio-tek). We also compared One-step RT-qPCR reagents: TaqMan Fast Virus 1-Step Master Mix (FastVirus, ThermoFisher Scientific), qPCRBIO Probe 1-Step Go Lo-ROX (PCR Biosystems) and Luna
    Language English
    Publishing date 2021-04-10
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2020.04.22.20074351
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top